---
title: "Purple Biotech Updates Investors on CAPTN-3 Platform and Pipeline as IM1240 Nears 2027 Clinic Entry"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290588048.md"
description: "Purple Biotech (PPBT) updated investors on its CAPTN-3 platform and lead candidate IM1240, expected to enter clinical trials in 2027. The company highlighted preclinical data showing strong anti-tumor activity and improved safety for solid tumors. With $6.4 million in cash, the runway extends into H1 2027. While some analysts rate it a Buy with a $30 target, TipRanks' AI suggests Neutral due to weak financials and technical indicators."
datetime: "2026-06-23T14:49:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290588048.md)
  - [en](https://longbridge.com/en/news/290588048.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290588048.md)
generator: "portal-rs"
---

# Purple Biotech Updates Investors on CAPTN-3 Platform and Pipeline as IM1240 Nears 2027 Clinic Entry

The latest announcement is out from Purple Biotech ( (PPBT) ).

On June 23, 2026, Purple Biotech filed a Form 6-K and released an updated corporate presentation outlining its CAPTN-3 tri-specific platform and lead candidate IM1240, which is expected to enter clinical trials in 2027. The company highlighted preclinical data suggesting strong anti-tumor activity with a markedly improved safety profile versus non-masked comparators, as well as a focused strategy on solid tumors, a cash position of $6.4 million as of March 31, 2026, and a runway into the first half of 2027, framing upcoming Phase 1 results from 2028 as a key value inflection point for investors.

The presentation underscored that Purple Biotech’s masked tri-specific T cell engager technology aims to address limitations of current therapies in solid tumors by enabling tumor-selective activation and dual engagement of T cells and NK cells. Management positioned the platform against a backdrop of large unmet need and high-value preclinical deal precedents for masked TCE programs, signaling potential partnership and monetization opportunities if early clinical proof-of-concept is achieved.

The most recent analyst rating on (PPBT) stock is a Buy  
 with a $30.00 price target.  
 To see the full list of analyst forecasts on Purple Biotech stock,  
 see the PPBT Stock Forecast page. 

**Spark’s Take on PPBT Stock**

According to Spark, TipRanks’ AI Analyst, PPBT is a Neutral.

The score is driven primarily by very weak financial performance (no meaningful revenue, large recurring losses, and ongoing cash burn, despite low leverage). Technicals add further pressure with the price far below key moving averages and negative momentum indicators. Valuation is also constrained by a negative P/E and no dividend yield support.

To see Spark’s full report on PPBT stock,  
 click here. 

**More about Purple Biotech**

Purple Biotech Ltd. is an Israeli immuno-oncology company listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker PPBT, focused on developing next-generation multi-specific T cell engagers for solid tumors. Its pipeline centers on tri-specific, masked T cell engager platforms such as IM1240 and IM1305, designed to activate both T cells and NK cells while improving safety and tumor selectivity.

**Average Trading Volume:** 301,178

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** $10.91M

### Related Stocks

- [PPBT.US](https://longbridge.com/en/quote/PPBT.US.md)

## Related News & Research

- [Purple Biotech Q1 2026 Results Highlight CAPTN-3 Pivot and IM1240 Preclinical Momentum](https://longbridge.com/en/news/286559312.md)
- [Purple Biotech presents new preclinical IM1240 cancer data at EACR 2026 congress](https://longbridge.com/en/news/295224384.md)
- [America Great Health reports interim data from ion-modified peptide adjunctive therapy observational study in solid tumors](https://longbridge.com/en/news/296824338.md)
- [Takeda adds boxed warning on ADZYNMA over risk of neutralizing antibodies to ADAMTS13](https://longbridge.com/en/news/296794493.md)
- [Monte Rosa doses first patient in Phase 2 MODeFIRe-1 trial of MRT-2359 plus apalutamide in mCRPC](https://longbridge.com/en/news/296776784.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**